Revised SPCs: Jakavi (ruxolitinib) Tablets- all strengths

SPCs has been revised to advise that the concomitant use of cytoreductive therapies with ruxolitinib was associated with manageable cytopenias and to refer to section 4.2 for dose modifications during cytopenias.

electronic Medicines compendium